NasdaqGM:AXSMPharmaceuticals
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)
In recent months, Axsome Therapeutics reported interim unaudited 2025 results pointing to strong product revenue growth, while its lead drug Auvelity secured priority FDA review for treating agitation in Alzheimer’s disease with an April 30, 2026 target action date.
These updates highlight how Axsome’s growing commercial footprint and expanding late-stage pipeline in central nervous system disorders could reshape the company’s long-term revenue mix if approvals and label expansions are...